医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

EdiGENE Changes Name to Modalis Therapeutics

2019年08月29日 AM11:32
このエントリーをはてなブックマークに追加


 

TOKYO & CAMBRIDGE, Mass.

EdiGENE Corporation today announced that the company has changed its name to Modalis Therapeutics Corporation. Modalis (pronounced “MO-DA-LIS”) is an original name that the Company has chosen to hope Company’s proprietary gene modulation technology, CRISPR-GNDM, to be a new modality (therapeutic technology) to assist patients fighting with genetic disorders.

“Our goal is to create CRISPR based gene therapies for genetic disorders, most of which fall into orphan disease. We think there should be no disease that can be ignored because of the small patient population and that our belief, ’Every Life Deserve Attention’, is achievable with power of our new technology. We are proud to be a front runner of CRISPR based gene modulation therapy,” said Haru Morita, chief executive officer at Modalis Therapeutics. “We decided to change our company name because the Modalis better reflects the emerging gene modulation technology that Company established and provides to the industries”. In conjunction with the corporate name change, the Company will have a new domain name modalistx.com

About Modalis

Modalis is an emerging biotech company that develops therapeutics using its proprietary technology CRISPR-GNDM. Our people, products, and partners believe “every life deserves attention” and our mission is to develop therapeutics primarily for genetic orphan disorders that affect fewer than 200,000 people or fewer than 1 in 2,000.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190828005804/en/

CONTACT

Modalis Therapeutics

Sawako Nakamura

media@modalistx.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 患者安全领导人和倡议人士讨论杜绝可预防患者死亡的解决方案
  • 3件の病院システムが患者安全運動財団より5つ星病院ランクを獲得
  • 武田获得2019年道琼斯可持续发展世界指数认可
  • Solasia宣布,Darinaparsin治疗T细胞淋巴瘤2期枢纽性研究患者登记达到目标病例数
  • Fusionex and IMU Introduce Big Data Analytics to Accelerate Medical Education and Research